Cannabidiolo (CBD) ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
156Rett syndrome1

156. Rett syndrome


Clinical trials : 40 Drugs : 53 - (DrugBank : 19) / Drug target genes : 77 - Drug target pathways : 113
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2018-003370-27-IT
(EUCTR)
18/09/201924/05/2021A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome.A randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of cannabidiol oral solution (GWP42003-P; CBD-OS) in patients with Rett syndrome. - Not applicable Rett syndrome (RTT) [typical or atypical]
MedDRA version: 20.0;Level: PT;Classification code 10077709;Term: Rett syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: CBD - Solution Orale, conosciuto come Epidiolex, questo è il nome approvato negli Stati Uniti
Product Name: Cannabidiolo (CBD)
Product Code: [GWP42003-P]
INN or Proposed INN: Cannabidiolo
Other descriptive name: Cannabidiol
GW RESEARCH LTD.NULLNot RecruitingFemale: yes
Male: no
252Phase 3United States;Canada;Spain;Germany;United Kingdom;Italy